Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.

Hyer ML, Milhollen MA, Ciavarri J, Fleming P, Traore T, Sappal D, Huck J, Shi J, Gavin J, Brownell J, Yang Y, Stringer B, Griffin R, Bruzzese F, Soucy T, Duffy J, Rabino C, Riceberg J, Hoar K, Lublinsky A, Menon S, Sintchak M, Bump N, Pulukuri SM, Langston S, Tirrell S, Kuranda M, Veiby P, Newcomb J, Li P, Wu JT, Powe J, Dick LR, Greenspan P, Galvin K, Manfredi M, Claiborne C, Amidon BS, Bence NF.

Nat Med. 2018 Feb;24(2):186-193. doi: 10.1038/nm.4474. Epub 2018 Jan 15.

PMID:
29334375
2.

Mechanistic study of Uba5 enzyme and the Ufm1 conjugation pathway.

Gavin JM, Hoar K, Xu Q, Ma J, Lin Y, Chen J, Chen W, Bruzzese FJ, Harrison S, Mallender WD, Bump NJ, Sintchak MD, Bence NF, Li P, Dick LR, Gould AE, Chen JJ.

J Biol Chem. 2014 Aug 15;289(33):22648-58. doi: 10.1074/jbc.M114.573972. Epub 2014 Jun 25.

3.

Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).

Duffey MO, Vos TJ, Adams R, Alley J, Anthony J, Barrett C, Bharathan I, Bowman D, Bump NJ, Chau R, Cullis C, Driscoll DL, Elder A, Forsyth N, Frazer J, Guo J, Guo L, Hyer ML, Janowick D, Kulkarni B, Lai SJ, Lasky K, Li G, Li J, Liao D, Little J, Peng B, Qian MG, Reynolds DJ, Rezaei M, Scott MP, Sells TB, Shinde V, Shi QJ, Sintchak MD, Soucy F, Sprott KT, Stroud SG, Nestor M, Visiers I, Weatherhead G, Ye Y, D'Amore N.

J Med Chem. 2012 Jan 12;55(1):197-208. doi: 10.1021/jm2011172. Epub 2011 Dec 5.

PMID:
22070629
4.

Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues.

Chen JJ, Tsu CA, Gavin JM, Milhollen MA, Bruzzese FJ, Mallender WD, Sintchak MD, Bump NJ, Yang X, Ma J, Loke HK, Xu Q, Li P, Bence NF, Brownell JE, Dick LR.

J Biol Chem. 2011 Nov 25;286(47):40867-77. doi: 10.1074/jbc.M111.279984. Epub 2011 Oct 3.

5.

Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

Blackburn C, Barrett C, Blank JL, Bruzzese FJ, Bump N, Dick LR, Fleming P, Garcia K, Hales P, Hu Z, Jones M, Liu JX, Sappal DS, Sintchak MD, Tsu C, Gigstad KM.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6581-6. doi: 10.1016/j.bmcl.2010.09.032. Epub 2010 Sep 15.

PMID:
20875739
6.

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.

Blackburn C, Gigstad KM, Hales P, Garcia K, Jones M, Bruzzese FJ, Barrett C, Liu JX, Soucy TA, Sappal DS, Bump N, Olhava EJ, Fleming P, Dick LR, Tsu C, Sintchak MD, Blank JL.

Biochem J. 2010 Sep 15;430(3):461-76. doi: 10.1042/BJ20100383. Erratum in: Biochem J. 2010 Oct 11;431(3):433.

7.

Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.

Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, Ma J, Loke HK, Lingaraj T, Wu D, Hamman KB, Spelman JJ, Cullis CA, Langston SP, Vyskocil S, Sells TB, Mallender WD, Visiers I, Li P, Claiborne CF, Rolfe M, Bolen JB, Dick LR.

Mol Cell. 2010 Jan 15;37(1):102-11. doi: 10.1016/j.molcel.2009.12.024.

8.

Purification and kinetic characterization of recombinant human mitogen-activated protein kinase kinase kinase COT and the complexes with its cellular partner NF-kappa B1 p105.

Jia Y, Quinn CM, Bump NJ, Clark KM, Clabbers A, Hardman J, Gagnon A, Kamens J, Tomlinson MJ, Wishart N, Allen H.

Arch Biochem Biophys. 2005 Sep 1;441(1):64-74.

PMID:
16087150
9.

Direct phosphorylation of NF-kappaB1 p105 by the IkappaB kinase complex on serine 927 is essential for signal-induced p105 proteolysis.

Salmerón A, Janzen J, Soneji Y, Bump N, Kamens J, Allen H, Ley SC.

J Biol Chem. 2001 Jun 22;276(25):22215-22. Epub 2001 Apr 10.

10.

Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis.

Datta R, Kojima H, Banach D, Bump NJ, Talanian RV, Alnemri ES, Weichselbaum RR, Wong WW, Kufe DW.

J Biol Chem. 1997 Jan 17;272(3):1965-9.

11.

Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35.

Bump NJ, Hackett M, Hugunin M, Seshagiri S, Brady K, Chen P, Ferenz C, Franklin S, Ghayur T, Li P, et al.

Science. 1995 Sep 29;269(5232):1885-8.

PMID:
7569933
12.

Identification and characterization of ICH-2, a novel member of the interleukin-1 beta-converting enzyme family of cysteine proteases.

Kamens J, Paskind M, Hugunin M, Talanian RV, Allen H, Banach D, Bump N, Hackett M, Johnston CG, Li P, et al.

J Biol Chem. 1995 Jun 23;270(25):15250-6.

13.

Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: a (p20/p10)2 homodimer.

Walker NP, Talanian RV, Brady KD, Dang LC, Bump NJ, Ferenz CR, Franklin S, Ghayur T, Hackett MC, Hammill LD, et al.

Cell. 1994 Jul 29;78(2):343-52.

PMID:
8044845
14.

The characteristics of purified HL60 tuftsin receptors.

Bump NJ, Najjar VA, Reichler J.

Mol Cell Biochem. 1990 Jan 18;92(1):77-84.

PMID:
2308578
15.

Covalent peptide transfer to cell membrane proteins (peptidyl transferase).

Najjar VA, Bump NJ.

FEBS Lett. 1989 Aug 14;253(1-2):129-31.

16.

Tuftsin stimulates growth of HL60 cells.

Bump NJ, Najjar VA.

FEBS Lett. 1988 Jan 4;226(2):303-6.

17.

Isolation and subunit composition of tuftsin receptor.

Bump NJ, Lee J, Wleklik M, Reichler J, Najjar VA.

Proc Natl Acad Sci U S A. 1986 Oct;83(19):7187-91. Erratum in: Proc Natl Acad Sci U S A 1987 Feb;84(4):963.

18.

Tuftsin (Thr-Lys-Pro-Arg), a natural modulator of macrophage activity: further studies.

Bump NJ, Najjar VA.

Mol Cell Biochem. 1984 Sep;63(2):137-42.

PMID:
6493218
19.

The similarity between tuftsin (Thr-Lys-Pro-Arg) receptors and tuftsin antibody: a case of induced molecular mimicry.

Chaudhuri MK, Konopińska D, Bump NJ, Najjar VA.

Ann N Y Acad Sci. 1983;419:135-42.

PMID:
6324634

Supplemental Content

Support Center